These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18028028)

  • 1. Flavin-containing monooxygenase 3 and human disease.
    Motika MS; Zhang J; Cashman JR
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):831-45. PubMed ID: 18028028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication.
    Cashman JR; Akerman BR; Forrest SM; Treacy EP
    Drug Metab Dispos; 2000 Feb; 28(2):169-73. PubMed ID: 10640514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotyping of flavin-containing monooxygenase using caffeine metabolism and genotyping of FMO3 gene in a Korean population.
    Park CS; Chung WG; Kang JH; Roh HK; Lee KH; Cha YN
    Pharmacogenetics; 1999 Apr; 9(2):155-64. PubMed ID: 10376762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism.
    Cashman JR
    Pharmacogenomics; 2002 May; 3(3):325-39. PubMed ID: 12052141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities.
    Shimizu M; Yano H; Nagashima S; Murayama N; Zhang J; Cashman JR; Yamazaki H
    Drug Metab Dispos; 2007 Mar; 35(3):328-30. PubMed ID: 17142560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimethylaminuria and a human FMO3 mutation database.
    Hernandez D; Addou S; Lee D; Orengo C; Shephard EA; Phillips IR
    Hum Mutat; 2003 Sep; 22(3):209-13. PubMed ID: 12938085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein beta (C/EBPbeta) liver inhibitory and liver activating proteins.
    Klick DE; Shadley JD; Hines RN
    Biochem Pharmacol; 2008 Jul; 76(2):268-78. PubMed ID: 18555208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavin-containing monooxygenases: mutations, disease and drug response.
    Phillips IR; Shephard EA
    Trends Pharmacol Sci; 2008 Jun; 29(6):294-301. PubMed ID: 18423897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
    Yamazaki H; Shimizu M
    Biochem Pharmacol; 2013 Jun; 85(11):1588-93. PubMed ID: 23567996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication.
    Cashman JR; Xiong YN; Xu L; Janowsky A
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1251-60. PubMed ID: 10027866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethylaminuria (fish odor syndrome): genotype characterization among Portuguese patients.
    Ferreira F; Esteves S; Almeida LS; Gaspar A; da Costa CD; Janeiro P; Bandeira A; Martins E; Teles EL; Garcia P; Azevedo L; Vilarinho L
    Gene; 2013 Sep; 527(1):366-70. PubMed ID: 23791655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers.
    Shimizu M; Shiraishi A; Sato A; Nagashima S; Yamazaki H
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):70-4. PubMed ID: 25760532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of structure and function of a catalytically efficient variant of the human flavin-containing monooxygenase form 3.
    Borbás T; Zhang J; Cerny MA; Likó I; Cashman JR
    Drug Metab Dispos; 2006 Dec; 34(12):1995-2002. PubMed ID: 16985102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
    Cashman JR; Zhang J
    Drug Metab Dispos; 2002 Oct; 30(10):1043-52. PubMed ID: 12228178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavin-containing monooxygenase 3 gene polymorphisms in Turkish population.
    Ozhan G; Topal P; Alpertunga B
    Toxicol Mech Methods; 2012 Jul; 22(6):461-5. PubMed ID: 22409263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
    Phillips IR; Shephard EA
    Xenobiotica; 2020 Jan; 50(1):19-33. PubMed ID: 31317802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The frequency distribution of flavin-containing monooxygenase 3 mutant alleles in 28 populations from Yunnan].
    Zeng WM; Yang J; Dong YL; Shi H; Gao L; Yang ZL; Lu J; Hao ZJ; Xiao CJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Aug; 20(4):318-21. PubMed ID: 12903042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism.
    Cashman JR
    Curr Drug Metab; 2000 Sep; 1(2):181-91. PubMed ID: 11465082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic polymorphism of FMO3 and its role in drug metabolism and toxicity].
    Gong Z; Wang Q
    Zhongguo Zhong Yao Za Zhi; 2015 Jul; 40(14):2701-5. PubMed ID: 26666012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3.
    Zhou J; Shephard EA
    Mutat Res; 2006 Jun; 612(3):165-171. PubMed ID: 16481213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.